

**Table S1** Effects of Trametinib on Proliferation of MGC803, MIA paca-2, and PANC-1 Cells.

Group (%)	MGC803(24hrs)		MGC803(48hrs)		MGC803(72hrs)	
	RS rate	SD	RS rate	SD	RS rate	SD
0	100	±5.24	100	±1.90	100	±4.54
5 µM	103.37	±2.10	93.95	±9.74	84.41	±5.68
10 µM	105.93	±4.25	99.54	±5.76	95.65	±3.63

Group (%)	MIA paca-2 (24 hrs)		MIA paca-2 (48 hrs)		MIA paca-2 (72 hrs)	
	RS rate	SD	RS rate	SD	RS rate	SD
0	100	±12.12	100	±7.90	100	±2.90
5 µM	85.91	±4.46	61.48	±5.52	35.46	±2.11
10 µM	81.75	±8.63	55.76	±7.77	19.65	±1.84

Group (%)	PANC-1 (24 hrs)		PANC-1 (48 hrs)		PANC-1 (72 hrs)	
	RS rate	SD	RS rate	SD	RS rate	SD
0	100	±10.87	100	±12.95	100	±3.50
5 µM	108.54	±9.15	88.46	±13.20	88.57	±4.50
10 µM	93.34	±9.15	83.23	±11.94	48.75	±8.54

RS: relative survival.

**Table S2** Effects of Fedratinib on Prolifertation of MGC803, MIA paca-2, and PANC-1 Cells for 24hrs

Group (%)	MGC803		MIA paca-2		PANC-1	
	RS rate	SD	RS rate	SD	RS rate	SD
0	100	±19.01	100	±25.80	100	±32.93
1 µM	116.40	±28.11	52.09	±0.74	88.48	±5.68
2 µM	75.49	±17.18	35.94	±5.65	86.47	±18.76
5 µM	47.77	±14.78	26.08	±4.54	72.67	±11.43

RS: relative survival.

**Table S3** Effects of Fedratinib and Trametinib alone or in combination on Proliferation of MGC803, MIA paca-2, and PANC-1 cells for 24 hrs

Group (%)	MGC803		MIA paca-1		PANC-1	
	RS rate	SD	RS rate	SD	RS rate	SD
0	100	±3.44	100	±11.87	100	±7.21
2 µM Fed	75.58	±3.25	67.97	±7.35	91.47	±11.40
10 µM Tra	93.43	±1.82	83.82	±10.52	86.41	±6.34
2 µM Fed + 10 µM	30.63	±4.59	28.99	±4.57	48.21	±1.73

RS: relative survival; Fed: Fedratinib; Tra: trametinib.

**Table S4** Percentage of Apoptotic MGC803 Cells (%) Treated at Indicated Concentrations of Fedratinib for 24 hrs

concentration (µM)	Percentage of apoptotic (%)
0	3.9 ±1.6
1	12.5±7.19
2	17 ±2.87
5	28 ±3.17

**Table S5** Effects of Fedratinib and Trametinib alone or in combination on MGC803 Cells Xenograft Tumor Volume

Group	Tumor volume (mm <sup>3</sup> )				
	0 day	3 <sup>rd</sup> day	6 <sup>th</sup> day	9 <sup>th</sup> day	11 <sup>th</sup> day
Control	133.41 ±38.7	212.02 ±74.94	286.55 ±120.17	413.95 ±131.74	495.27 ±134.47
Fed (30 mg/kg)	128.9 ±38.84	175.35 ±30.69	273.87 ±39.23	386.07 ±71.34	393.74.72 ±53.07
Tra (0.75 mg/kg)	125.74±33 .65	191.59 ±30.75	227.86 ±77.72	342.08 ±59.39	425.03 ±60.43
30 mg/kg Fed+ 0.75 mg/kg Tra	113.33±29 .35	122.35 ±22.80	148.00 ±34.75	237.81 ±86.68	279.55 ±99.72

Fed: Fedratinib; Tra: trametinib.

**Table S6** Effects of Fedratinib and Trametinib alone or in combination on Tumor Weight and Tumor Suppression Rate

Group	Tumor weight (g)						Tumor suppression rate (%)
	1	2	3	4	5	6	
Control	1.420	1.059	0.782	0.534	0.564	0.471	0
Fed (30 mg/kg)	1.061	0.675	0.464	0.709	0.434	0.373	23.06±25.51
Tra (0.75 mg/kg)	0.748	0.536	0.512	0.378	0.383	0.283	41.20±16.39
30 mg/kg Fed+ 0.75 mg/kg Tra	0.272	0.246	0.259	0.270	0.269	0.303	66.48±1.89

Fed: Fedratinib; Tra: trametinib.

Supplemental Figures legends

Fig. S1 Addition of Fedratinib and Trametinib alone or in combination does not affect body weight of mice bearing MGC-803 cells xenograft tumor during observed period.

